Lei et al. demonstrated that CIP2A overexpression enhances EGF-induced AKT phosphorylation in NSCLC models [35], while CIP2A knockdown reduces p-AKT and downstream oncogenic activity [36,37]. The gene discussed is CIP2A; the disease is non-small cell lung carcinoma.